Photo: AInvest / iStock
BEIJING, 5 September (BelTA - China Daily) - The Chinese company Jiangsu
Hengrui Pharmaceuticals said in a statement that it has received
conditional approval from the National Medical Products Administration
for its new cancer drug, Zeprumetostat.
The treatment has been cleared for use by adult patients with relapsed or refractory peripheral T-cell lymphoma who have already received at least one systemic therapy. R/R PTCL is a rare and aggressive blood cancer with limited treatment options.
Zeprumetostat is China's first domestically developed EZH2 inhibitor. EZH2 is an enzyme tied to cancer cell growth, and drugs targeting it are seen as a promising approach in oncology. Hengrui describes its product as a selective, oral therapy designed to offer new hope for patients.
Under conditional approval, the medicine can be marketed while the company continues to supply longer-term clinical data on safety and effectiveness.
The treatment has been cleared for use by adult patients with relapsed or refractory peripheral T-cell lymphoma who have already received at least one systemic therapy. R/R PTCL is a rare and aggressive blood cancer with limited treatment options.
Zeprumetostat is China's first domestically developed EZH2 inhibitor. EZH2 is an enzyme tied to cancer cell growth, and drugs targeting it are seen as a promising approach in oncology. Hengrui describes its product as a selective, oral therapy designed to offer new hope for patients.
Under conditional approval, the medicine can be marketed while the company continues to supply longer-term clinical data on safety and effectiveness.
Follow us on:
